| CORBUS PHARMACEUTICALS |
| USA |
| Gesundheit |
| US21833P3010 / A3D54P |
| 3371 (Frankfurt) / CRBP (NASDAQ) |
| FRA:3371, ETR:3371, 3371:GR, NASDAQ:CRBP |
| - |
| https://www.corbuspharma... |
|
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Corbus Pharmaceuticals Holdings, Inc. advances a pipeline centered on targeted treatments, including CRB-701..
>Volltext.. |
| 135.45 Mio. EUR |
| 35.83 Mio. EUR |
| - |
| -92.42 Mio. EUR |
| -88.32 Mio. EUR |
| -5.35 EUR |
| 3.7 Mio. EUR |
| 20.26 Mio. EUR |
| -75.12 Mio. EUR |
| 5.49 |
| - |
| -81.37% |
| - |
| - |
| - |
| CORBUS PHARMACEUTICALS, CORBUS PHARMA, CORBUS PHARMACEUTICAL |
| 16.09.26 |